← Leaderboards
Jaroslaw A. Aronowski
University Of Texas Hlth Sci Ctr Houston
$13,611,686
Attributed
$16,844,564
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,844,564 · 12
By mechanism
R01$13,490,598 · 8
R42$1,604,091 · 1
U01$1,128,148 · 1
R21$385,000 · 1
R41$236,727 · 1
Top collaborators
- Joo Eun Jung5 shared
- Marian L Kruzel4 shared
- Xiurong Zhao4 shared
- Sean I Savitz1 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Joo Eun Jung$2,162,787
- Spiros Blackburn$1,147,300
- Xiurong Zhao$2,896,091
- Jocelyne H Bachevalier$13,246,208
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainMediatingMacrophageAffectMicrogliaBaseAnti-Inflammatory AgentsStrokeBrain InjuriesInflammatory ResponseRecoveryCerebral Hemisphere HemorrhagePhenotypeInflammationPhagocytosisNeuronsPhagocytesBloodCellsProteinsHematomaClinically RelevantEffective TherapyAnimals
Grant awards (47)
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH$471,323
R01 · FY2025 · NS · contact PI
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH$457,184
R01 · FY2024 · NS · contact PI
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH$471,323
R01 · FY2023 · NS · contact PI
Humanin and Intracerebral Hemorrhage$470,547
R01 · FY2023 · NS · contact PI
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH$471,323
R01 · FY2022 · NS · contact PI
Humanin and Intracerebral Hemorrhage$470,547
R01 · FY2022 · NS · contact PI
Stroke Preclinical Assessment Network (SPAN) â Tacilizumab for treatment of acute ischemic stroke$506,905
U01 · FY2021 · NS · contact PI
Humanin and Intracerebral Hemorrhage$476,982
R01 · FY2021 · NS · contact PI
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH$464,888
R01 · FY2021 · NS · contact PI
Stroke Preclinical Assessment Network (SPAN) â Tacilizumab for treatment of acute ischemic stroke$505,854
U01 · FY2020 · NS · contact PI
Humanin and Intracerebral Hemorrhage$472,906
R01 · FY2020 · NS · contact PI
Neutrophils in Recovery after ICH$410,616
R01 · FY2020 · NS · contact PI
Humanin and Intracerebral Hemorrhage$484,238
R01 · FY2019 · NS · contact PI
Neutrophils in Recovery after ICH$336,875
R01 · FY2019 · NS · contact PI
Stroke Preclinical Assessment Network (SPAN) â Tacilizumab for treatment of acute ischemic stroke$115,389
U01 · FY2019 · NS · contact PI
Neutrophils in Recovery after ICH$73,741
R01 · FY2019 · NS · contact PI
DMF for intracerebral hemorrhage$385,000
R21 · FY2018 · NS
Neutrophils in Recovery after ICH$336,875
R01 · FY2018 · NS · contact PI
Optimized lactoferrin for treatment of intracerebral hemorrhage$827,468
R42 · FY2017 · NS
Neutrophils in Recovery after ICH$336,875
R01 · FY2017 · NS · contact PI
Treatment of secondary injury after ischemic stroke through targeting microglia$332,500
R01 · FY2017 · NS · contact PI
Optimized lactoferrin for treatment of intracerebral hemorrhage$776,623
R42 · FY2016 · NS
Neutrophils in Recovery after ICH$336,875
R01 · FY2016 · NS · contact PI
Treatment of secondary injury after ischemic stroke through targeting microglia$332,500
R01 · FY2016 · NS · contact PI
Treatment of secondary injury after ischemic stroke through targeting microglia$332,500
R01 · FY2015 · NS · contact PI
Optimized lactoferrin for treatment of intracerebral hemorrhage$47,600
R41 · FY2015 · NS
Treatment of secondary injury after ischemic stroke through targeting microglia$329,174
R01 · FY2014 · NS · contact PI
Optimized lactoferrin for treatment of intracerebral hemorrhage$189,127
R41 · FY2014 · NS
Treatment of secondary injury after ischemic stroke through targeting microglia$332,500
R01 · FY2013 · NS · contact PI
Pleiotropic Transcription Factors As Target For Intracerebral Hemorrhage Treatmen$321,563
R01 · FY2012 · NS · contact PI
Pleiotropic Transcription Factors As Target For Intracerebral Hemorrhage Treatmen$321,563
R01 · FY2011 · NS · contact PI
Pleiotropic Transcription Factors As Target For Intracerebral Hemorrhage Treatmen$324,845
R01 · FY2010 · NS · contact PI
Pleiotropic Transcription Factors As Target For Intracerebral Hemorrhage Treatmen$328,125
R01 · FY2009 · NS · contact PI
Pleiotropic Transcription Factors As Target For Intracerebral Hemorrhage Treatmen$327,852
R01 · FY2008 · NS · contact PI
New Target For Stroke: Peroxisome Proliferator Activated Receptor-Gamma$288,387
R01 · FY2008 · NS · contact PI
New Target For Stroke: Peroxisome Proliferator Activated Receptor-Gamma$288,387
R01 · FY2007 · NS · contact PI
New Target For Stroke: Peroxisome Proliferator Activated Receptor-Gamma$297,000
R01 · FY2006 · NS · contact PI
Etiology of cellular damage after experimental stroke$334,125
R01 · FY2005 · NS
Novel treatment for stroke:$74,271
R01 · FY2005 · NS
Etiology of cellular damage after experimental stroke$334,125
R01 · FY2004 · NS
Novel treatment for stroke:$259,875
R01 · FY2004 · NS
Etiology of cellular damage after experimental stroke$334,219
R01 · FY2003 · NS
Novel treatment for stroke:$259,948
R01 · FY2003 · NS
Etiology of cellular damage after experimental stroke$335,344
R01 · FY2002 · NS
Novel treatment for stroke:$260,823
R01 · FY2002 · NS
Etiology of cellular damage after experimental stroke$336,375
R01 · FY2001 · NS
Novel treatment for stroke:$261,479
R01 · FY2001 · NS